Wenrui Gu1, Qiong Yu2, Cuixiang Yu3, Shujuan Sun4. 1. School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong Province, PR China; Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, PR China. 2. Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, PR China. 3. Respiration Medicine, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong Province, PR China. 4. Department of Pharmacy, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong Province, PR China. Electronic address: sunshujuan888@163.com.
Abstract
OBJECTIVES: Treatment of azole-resistant Candida albicans infections continues to pose significant challenges. With limited options of licensed agents, drug combinations may be a practical treatment alternative. In our previous studies, the combinations minocycline/fluconazole (MINO/FLC) and doxycycline/fluconazole (DOXY/FLC) shown synergistic effects in vitro. It is necessary to explore their appropriate dosage, potential toxicity and in vivo efficacy. METHODS: The Galleria mellonella infection model was employed to study the in vivo efficacy of MINO/FLC and DOXY/FLC by survival analysis, quantification of C. albicans fungal burden and histological studies. RESULTS: The survival rates of G. mellonella larvae infected with lethal doses of resistant C. albicans CA10 increased significantly when treated with the drug combinations compared with FLC treatment alone, and the fungal burden was reduced by almost four-fold. The histopathological study showed that fewer infected areas in larvae were observed and the destructive degree was less when larvae were exposed to the drug combinations. CONCLUSIONS: These findings suggest that combination of a tetracycline antibiotic (MINO or DOXY) with FLC has antifungal activity against azole-resistant C. albicans in vivo. This is in agreement with several previous in vitro studies and provides preliminary in vivo evidence that such a combination might be useful therapeutically.
OBJECTIVES: Treatment of azole-resistant Candida albicans infections continues to pose significant challenges. With limited options of licensed agents, drug combinations may be a practical treatment alternative. In our previous studies, the combinations minocycline/fluconazole (MINO/FLC) and doxycycline/fluconazole (DOXY/FLC) shown synergistic effects in vitro. It is necessary to explore their appropriate dosage, potential toxicity and in vivo efficacy. METHODS: The Galleria mellonella infection model was employed to study the in vivo efficacy of MINO/FLC and DOXY/FLC by survival analysis, quantification of C. albicans fungal burden and histological studies. RESULTS: The survival rates of G. mellonella larvae infected with lethal doses of resistant C. albicans CA10 increased significantly when treated with the drug combinations compared with FLC treatment alone, and the fungal burden was reduced by almost four-fold. The histopathological study showed that fewer infected areas in larvae were observed and the destructive degree was less when larvae were exposed to the drug combinations. CONCLUSIONS: These findings suggest that combination of a tetracycline antibiotic (MINO or DOXY) with FLC has antifungal activity against azole-resistant C. albicans in vivo. This is in agreement with several previous in vitro studies and provides preliminary in vivo evidence that such a combination might be useful therapeutically.
Authors: Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen Journal: Microb Cell Date: 2018-06-14
Authors: Freya Cools; Eveline Torfs; Juliana Aizawa; Bieke Vanhoutte; Louis Maes; Guy Caljon; Peter Delputte; Davie Cappoen; Paul Cos Journal: Front Microbiol Date: 2019-02-21 Impact factor: 5.640
Authors: Beatriz Suay-García; Pedro A Alemán-López; José Ignacio Bueso-Bordils; Antonio Falcó; Gerardo Antón-Fos; María Teresa Pérez-Gracia Journal: Virulence Date: 2019-12 Impact factor: 5.882
Authors: Rafael M Gandra; Pauraic McCarron; Livia Viganor; Mariana Farias Fernandes; Kevin Kavanagh; Malachy McCann; Marta H Branquinha; André L S Santos; Orla Howe; Michael Devereux Journal: Front Microbiol Date: 2020-03-24 Impact factor: 5.640